Related Experiment Videos
Antiplatelet drugs induce apoptosis in cultured cancer cells
1Department of Neurology, Kaohsiung Medical College Hospital, Taiwan, Republic of China.
Abstract:
In order to understand if antiplatelet drugs possess direct antineoplastic property, we tested the apoptotic effect of 5 popularly marketed antiplatelet drugs in Taiwan in 6 cultured cancer cell lines (Hep 3B hepatocarcinoma, U87-MG malignant glioma, PC-3 prostate adenocarcinoma, HeLa cervical adenocarcinoma, HL-60 preleukemia and K-562 chronic myelogenous leukemia). While acetylsalicylate and flunarizine exerted no effect on these cancer cells, pentoxifyline (PTX), dipyridamole (DYA) and ticlopidine hydrochloride (T. HCl) displayed a time and dose-dependent apoptotic effect on them except for HL-60 and K-562 cells. PTX induced apoptosis in U87-MG, Hep 3B and HeLa cells, DYA in HeLa cells, while T. HCl in U87-MG, Hep 3B, PC-3 and HeLa cells. Adriamycin also provoked apoptotic effect in all 6 cell lines but neither PTX, DYA nor T. HCl acted synergy with adriamycin to HeLa cells, implicating that they may share a similar pathway for inducing apoptosis. Therefore, our results show that the antiplatelet drugs do possess antineoplastic property in vitro. A co-administration of antiplatelet drugs is noteworthy for an alternative adjunctive therapy in cancer patients.
Insights
Certain antiplatelet drugs, including pentoxifyline, dipyridamole, and ticlopidine hydrochloride, show direct antineoplastic effects by inducing cancer cell apoptosis in vitro. This suggests potential as an alternative adjunctive cancer therapy.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Antiplatelet drugs are widely used for cardiovascular conditions.
- Their potential antineoplastic properties remain largely unexplored.
- Understanding drug mechanisms is crucial for novel therapeutic strategies.
Purpose of the Study:
- To investigate the direct antineoplastic effects of commonly used antiplatelet drugs.
- To assess the apoptotic potential of these drugs across various human cancer cell lines.
- To explore potential synergistic interactions with conventional chemotherapy.
Main Methods:
- Cultured six human cancer cell lines: Hep 3B, U87-MG, PC-3, HeLa, HL-60, and K-562.
- Tested five antiplatelet drugs: acetylsalicylate, flunarizine, pentoxifyline (PTX), dipyridamole (DYA), and ticlopidine hydrochloride (T. HCl).
- Evaluated time- and dose-dependent apoptotic effects, comparing with Adriamycin.
Main Results:
- Pentoxifyline (PTX), dipyridamole (DYA), and ticlopidine hydrochloride (T. HCl) induced apoptosis in cancer cells, with varying efficacy across cell lines (except HL-60 and K-562).
- PTX affected U87-MG, Hep 3B, and HeLa cells; DYA affected HeLa cells; T. HCl affected U87-MG, Hep 3B, PC-3, and HeLa cells.
- No synergistic effect was observed between PTX, DYA, T. HCl, and Adriamycin in HeLa cells, suggesting shared apoptotic pathways.
Conclusions:
- Selected antiplatelet drugs exhibit direct in vitro antineoplastic activity.
- Pentoxifyline, dipyridamole, and ticlopidine hydrochloride demonstrate promising apoptotic effects on cancer cells.
- Co-administration of these antiplatelet drugs may represent a viable alternative adjunctive therapy for cancer patients.